CT-P13 SC was compared to (1) CT-P13 IV (from studies 3.1 and 3.5), (2) reference infliximab IV (from study 3.1) and (3) pooled data including both reference infliximab IV and CT-P13 IV (from studies 3.1 and 3.5).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.